Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study.
about
LHRH agonists for adjuvant therapy of early breast cancer in premenopausal womenReply to F. Tomao et al.A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort studyPatterns of change in cognitive function with anastrozole therapy.Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing.The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progrePatient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.Is HRT justified for symptom management in women at higher risk of developing breast cancer?Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors.Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.Hormonal therapies in young breast cancer patients: when, what and for how long?Quality of life and adjuvant systemic therapy for early-stage breast cancer.Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node-Negative, Hormone-Responsive, HER2-Negative, T1-T2 BreaQuality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009).Interventions for sexual problems following treatment for breast cancer: a systematic review.Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review.New insights into endocrine therapy for young women with breast cancer.The menopause specialist and breast cancer survivorship.History of oral contraceptive use in breast cancer patients: impact on prognosis and endocrine treatment response.Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy.Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.Factors associated with return to work after breast cancer treatment.Estimation of anxiety and depression in patients with early stage breast cancer before and after radiation therapy.Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant).Post-chemotherapy serum anti-Müllerian hormone level predicts ovarian function recovery
P2860
Q24240015-C6975601-884B-4053-BB74-8AA60B84BD7FQ33816570-42AA3AF9-49A2-49E6-9303-988400EA66A5Q34252972-178BFF83-9444-4D56-AA17-B0E80F413D2DQ35883135-2BE1A318-9B43-4EFB-A718-2CB37746B85CQ35966481-2B060632-82B6-430C-83BC-0CF6C5F8CDE3Q36022957-954A8FF2-8F44-48ED-8F51-CC6FD86E89EBQ36036025-7800E01A-56C5-49A3-821B-1B004A3AC950Q36645276-1F685165-2A1F-4D06-92D7-ED9F18BE0B33Q36689052-95DCB097-4AF9-49A5-8727-49C9AFD1711BQ36815909-4E66F1D8-C14C-4A31-B6EA-83ADB3F9C145Q36915190-CC0D57D4-44EA-42E2-B151-CF6902A4128FQ36963393-3A91A85C-2F41-4F4B-AC07-449080343535Q37008863-06633F63-BC89-450F-9233-F0A4BC9A2AEBQ37367441-6EB68329-C034-444F-8C0A-EB029954E8ECQ37827010-A34E3F30-04FE-474A-B3E6-2296338E97B9Q37929635-7C4D82C7-2032-42AD-B514-E7DBB11ADE2FQ37978292-A72B8C02-116A-4AD6-8F5B-98D0C1931D22Q38535371-D6390595-AA36-485D-931C-1B38AECFF9B2Q38955479-097CD9AA-A6C7-4BEB-96FA-79D77160E620Q41629178-D29C68F1-034B-4602-A637-FE20709B8700Q45242226-33A3314F-AC0D-46A8-827C-650B78923DFCQ45264473-2CA69BD6-A272-458F-9E92-A65822BF87EFQ48405268-859D259E-BD9A-43C8-A112-D35E3543D785Q49056399-24182E4A-F835-479D-B3CB-A47BDD6D965DQ55403230-A021F620-F689-49EC-9379-BB09084C5B75Q57301014-AEDFE1A9-E0A7-4DC0-A098-D6FF399FDA80
P2860
Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Side effects of adjuvant endoc ...... prospective randomized study.
@en
Side effects of adjuvant endoc ...... prospective randomized study.
@nl
type
label
Side effects of adjuvant endoc ...... prospective randomized study.
@en
Side effects of adjuvant endoc ...... prospective randomized study.
@nl
prefLabel
Side effects of adjuvant endoc ...... prospective randomized study.
@en
Side effects of adjuvant endoc ...... prospective randomized study.
@nl
P2093
P356
P1476
Side effects of adjuvant endoc ...... prospective randomized study.
@en
P2093
Christina Bolund
Gunilla Berglund
Lars Erik Rutqvist
Marianne Nystedt
Tommy Fornander
P304
P356
10.1200/JCO.2003.04.024
P407
P577
2003-05-01T00:00:00Z